Sander Slootweg Sander is Managing Partner at Forbion. He currently serves on the boards of Forbion’s portfolio companies Replimune, NewAmsterdam Pharma (Chair), Azafaros, Xention and Oxyrane. Sander was responsible for several substantial exits: Forbion’s substantial...
Rob de Ree Chief Executive Officer Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of the start-up companies Dezima Pharma, which was acquired by Amgen in 2015 and as the CEO of BMEYE which was acquired by Edwards lifesciences in 2012. Before...
Morris J. Birnbaum Morris J. Birnbaum, M.D., Ph.D. is a physician scientist who has led research teams investigating fundamental problems in metabolic regulation and their relevance to chronic disease in both academic and pharmaceutical settings. After a lengthy...
Jordi Xiol Jordi Xiol is a Principal at Ysios Capital. He currently serves on the board of Northsea Therapeutics, and as an observer on the board of Adcendo, Cytoki and Splice Bio. Jordi has more than 10 years’ experience in biomedical research. He completed a PhD at...
Dirk Kersten Dirk is a General Partner at Forbion and manages the Forbion Growth Opportunities Fund. Dirk is a physicist by training and previously worked as a Partner at Gilde Healthcare Partners, where he led their Boston/US operations. Furthermore Dirk was a...
